OLYSIO

is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen with peginterferon-alfa and ribavirin (P/R), in HCV genotype 1 (G1) infected subjects with compensated liver disease (including cirrhosis).  Read more about Olysio